Lucinda Crabtree joins Oxford
Biomedica as Chief Financial Officer today
Oxford, UK - 2 September 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or
"the Company"), a quality and innovation-led cell and gene therapy
CDMO, announces that Lucinda (Lucy) Crabtree Ph.D. has today joined
Oxford Biomedica as Chief Financial Officer (CFO) and board member.
Lucinda's appointment was previously
announced on 17 July 2024.
Lucinda Crabtree was previously at
MorphoSys AG where she served as CFO, leading a finance team across
the US and Germany until the company's acquisition by Novartis.
Previously, she was CFO at Autolus Therapeutics, a Nasdaq listed
clinical stage biopharmaceutical company. Lucinda also brings
extensive experience from the investment and banking sectors,
having held roles at institutions including Woodford Investment
Management, Goldman Sachs, and Jefferies.
Dr.
Frank Mathias, Chief Executive Officer of Oxford Biomedica,
commented: "We are thrilled that Lucy
has joined Oxford Biomedica as our new CFO and Board member today.
Lucy brings a wealth of experience from her roles as a CFO and time
as a healthcare investor and equity research analyst. Her
experience will be invaluable as we grow our international position
as a leading cell and gene therapy CDMO."
Lucinda Crabtree, Chief Financial Officer of Oxford Biomedica
said: "I am excited to be joining
Oxford Biomedica as CFO today. I firmly believe in the Company's
growth strategy and am looking forward to working with the Board
and the rest of the leadership team. Together, I'm confident we
will fulfil our mission of enabling our growing client base to
deliver life-changing therapies to patients."
-Ends-
Enquiries:
Oxford Biomedica plc:
Sophia Bolhassan, Head of Investor
Relations - T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR
Consilium:
T: +44 (0)20 3709 5700 /
E: oxfordbiomedica@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a
quality and innovation-led contract development and manufacturing
organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients
around the world.
One of the original
pioneers in cell and gene therapy, OXB has more than 25 years of
experience in viral vectors; the driving force behind the majority
of cell and gene therapies. OXB collaborates with some of the
world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and
manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. Oxford Biomedica's
world-class capabilities span from
early-stage development to
commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods
and depth of regulatory expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the
TetravectaTM
system), dual plasmid system for AAV production,
suspension and perfusion process using process enhancers and stable
producer and packaging cell lines.
Oxford Biomedica, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us
on LinkedIn and YouTube.